This month, our CEO Bas Oosterman was invited, together with The Protein Brewery and Novonesis, to take part in a roundtable with Dutch policymakers on the future of biotech in the Netherlands and Europe.

The conversation made clear how much biotech potential exists in the Dutch and European ecosystem, and also what will be needed going forward in a period of major transition. There is both the energy and the shared ambition to work toward a well-functioning biotech ecosystem, where societal transitions and economic value creation go hand in hand.

One clear takeaway: translating innovation into patient and societal impact requires close alignment between policy, regulation and investment. For a company like SentryX, working at the intersection of healthcare innovation and public health challenges, that alignment is key to bringing new solutions to patients faster.

Many thanks to HollandBIO and all participants for bringing this conversation together.